Study of ipratropium bromide inhalation in stable asthma.
An open two weeks short term trial of Ipratropium Bromide (IB) inhalation (0.02 mg per dose) was carried out in 20 stable asthamatics to study its efficacy and safety. Early significant rise in PEFR (P < 0.001) and FEV1 (P < 0.05) was observed after 15 min of IB inhalation and reached significant peak (P < 0.01) after 1 hour which was persistent beyond three hours after IB inhalation. No side effects were observed. It was concluded that Ipratropium Bromide Imhalation is safe and has efficient bronchodilatory effect on short term basis in stable asthmatics.
Ailani
R K
RK
Dept. of Respiratory Medicine, B.Y.L. Nair Hospital, Bombay.
Shah
S P
SP
Koyande
D
D
Kudalkar
S S
SS
Kodge
K
K
Deshmukh
Y A
YA
D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000517:prevention & control*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D009241:Ipratropium / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D010366:Peak Expiratory Flow Rate / Q000187:drug effects; D012449:Safety; D013997:Time Factors; D014797:Vital Capacity / Q000187:drug effects
D001993:Bronchodilator Agents; D009241:Ipratropium